Vaxart, Inc. - Quarter Report: 2017 December (Form 10-Q)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
|
☒ |
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
|
|
For the quarterly period ended December 31, 2017 |
or
|
☐ |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
|
|
For the transition period from to |
Commission file number: 001-35285
Aviragen Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
59-1212264 |
|
(State or other jurisdiction of incorporation or organization) |
|
(I.R.S. Employer Identification No.) |
2500 Northwinds Parkway, Suite 100, Alpharetta, GA 30009
(Address of principal executive offices, including zip code)
(678) 221 3343
(Registrant’s telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
|
Large accelerated filer |
|
☐ |
|
Accelerated filer |
|
☐ |
|
|
|
|
|
|||
|
Non-accelerated filer |
|
☐ |
|
Smaller reporting company |
|
☒ |
|
Emerging growth company |
☐ |
|||||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒
APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS DURING THE PRECEDING FIVE YEARS:
Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. Yes ☐ No ☒
The number of shares outstanding of the registrant’s common stock, par value $0.10 per share at February 5, 2018 was 38,649,237 shares.
ITEM 1. Financial Statements
Aviragen Therapeutics, Inc.
Condensed Consolidated Balance Sheets
(unaudited)
(in millions, except share amounts)
|
December 31, 2017 |
June 30, 2017 |
|||||||
|
ASSETS |
||||||||
|
Current assets: |
||||||||
|
Cash and cash equivalents |
$ | 29.4 | $ | 17.7 | ||||
|
Short-term investments |
- | 20.9 | ||||||
|
Accounts receivable, net of allowance |
2.5 | 0.6 | ||||||
|
Prepaid and other current assets |
0.5 | 0.7 | ||||||
|
Total current assets |
32.4 | 39.9 | ||||||
|
Non-current assets: |
||||||||
|
Property and equipment, net |
0.2 | 0.2 | ||||||
|
Total assets |
$ | 32.6 | $ | 40.1 | ||||
|
LIABILITIES AND STOCKHOLDERS’ EQUITY |
||||||||
|
Current liabilities: |
||||||||
|
Accounts payable |
$ | 1.7 | $ | 1.4 | ||||
|
Accrued expenses |
2.5 | 2.9 | ||||||
|
Short-term note payable |
0.3 | 0.2 | ||||||
|
Liability related to sale of future royalties, current portion |
1.2 | 1.4 | ||||||
|
Total current liabilities |
5.7 | 5.9 | ||||||
|
Non-current liabilities: |
||||||||
|
Long-term note payable, net of current portion |
- | 0.1 | ||||||
|
Liability related to sale of future royalties, net of current portion |
16.0 | 15.3 | ||||||
|
Other long-term liabilities, net of current portion |
0.1 | 0.1 | ||||||
|
Total liabilities |
21.8 | 21.4 | ||||||
|
Commitments and contingencies |
- | - | ||||||
|
Stockholders’ equity: |
||||||||
|
Preferred stock, $0.10 par value: 5,000,000 shares authorized, no shares issued and outstanding |
- | - | ||||||
|
Common stock, $0.10 par value: 200,000,000 shares authorized; 38,649,237 shares issued and outstanding at December 31, 2017 and June 30, 2017 |
3.9 | 3.9 | ||||||
|
Additional paid-in capital |
160.4 | 159.6 | ||||||
|
Accumulated other comprehensive income |
19.0 |
19.0 |
||||||
|
Accumulated deficit |
(172.5 |
) |
(163.8 |
) |
||||
|
Total stockholders’ equity |
10.8 | 18.7 | ||||||
|
Total liabilities and stockholders’ equity |
$ | 32.6 | $ | 40.1 | ||||
The accompanying notes are an integral part of these condensed consolidated financial statements.
Aviragen Therapeutics, Inc.
Condensed Consolidated Statements of Operations
(unaudited)
(in millions, except share and per share amounts)
|
Three Months Ended |
Six Months Ended |
|||||||||||||||
|
2017 |
2016 |
2017 |
2016 |
|||||||||||||
|
Revenue: |
||||||||||||||||
|
Royalty revenue |
$ | - | $ | 1.5 | $ | - | $ | 1.6 | ||||||||
|
Non-cash royalty revenue related to the sale of future royalties |
2.7 | 2.3 | 2.8 | 2.3 | ||||||||||||
|
Total revenue |
2.7 | 3.8 | 2.8 | 3.9 | ||||||||||||
|
Operating expense: |
||||||||||||||||
|
Research and development |
2.5 | 10.2 | 5.3 | 17.8 | ||||||||||||
|
General and administrative |
3.1 | 2.1 | 5.4 | 4.3 | ||||||||||||
|
Foreign exchange (gain) loss, net |
- | 0.1 | - | - | ||||||||||||
|
Total operating expense |
5.6 | 12.4 | 10.7 | 22.1 | ||||||||||||
|
Loss from operations |
(2.9 |
) |
(8.6 |
) |
(7.9 |
) |
(18.2 |
) |
||||||||
|
Other (expense) income: |
||||||||||||||||
|
Non-cash interest expense on liability related to sale of future royalties |
(0.4 |
) |
(0.5 |
) |
(0.8 |
) |
(0.9 |
) |
||||||||
|
Interest income |
- | 0.1 | 0.1 | 0.1 | ||||||||||||
|
Total other (expense) income |
(0.4 |
) |
(0.4 |
) |
(0.7 |
) |
(0.8 |
) |
||||||||
|
Loss before tax |
(3.3 |
) |
(9.0 |
) |
(8.6 |
) |
(19.0 |
) |
||||||||
|
Income tax expense |
0.1 | 0.1 | 0.1 | 0.1 | ||||||||||||
|
Net loss |
$ | (3.4 |
) |
$ | (9.1 |
) |
$ | (8.7 |
) |
$ | (19.1 |
) |
||||
|
Basic and diluted net loss per share |
$ | (0.09 |
) |
$ | (0.24 |
) |
$ | (0.23 |
) |
$ | (0.49 |
) |
||||
|
Basic and diluted weighted-average shares outstanding |
38,649,237 | 38,640,487 | 38,649,237 | 38,640,487 | ||||||||||||
The accompanying notes are an integral part of the condensed consolidated financial statements.
Aviragen Therapeutics, Inc.
Condensed Consolidated Statement of Stockholders’ Equity
(unaudited)
(in millions, except for share amounts)
|
Common Stock |
Accumulated |
|||||||||||||||||||||||
|
Shares |
Amount |
Additional Paid-in Capital |
Accumulated Deficit |
Other Comprehensive Income |
Total Stockholders’ Equity |
|||||||||||||||||||
|
Balances at June 30, 2017 |
38,649,237 | $ | 3.9 | $ | 159.6 | $ | (163.8 |
) |
$ | 19.0 | $ | 18.7 | ||||||||||||
|
Net loss |
- | - | - | (8.7 |
) |
- | (8.7 |
) |
||||||||||||||||
|
Share-based compensation |
- | - | 0.8 | - | - | 0.8 | ||||||||||||||||||
|
Balances at December 31, 2017 |
38,649,237 | $ | 3.9 | $ | 160.4 | $ | (172.5 |
) |
$ | 19.0 | $ | 10.8 | ||||||||||||
The accompanying notes are an integral part of these condensed consolidated financial statements.
Aviragen Therapeutics, Inc.
Condensed Consolidated Statements of Cash Flows
(unaudited)
(in millions)
|
Six Months Ended |
||||||||
|
2017 |
2016 |
|||||||
|
Cash flows from operating activities: |
||||||||
|
Net loss |
$ | (8.7 |
) |
$ | (19.1 |
) |
||
|
Adjustments to reconcile net loss to net cash used in operating activities: |
||||||||
|
Share-based compensation |
0.8 | 0.9 | ||||||
|
Non-cash interest expense related to sale of future royalties |
0.8 | 0.9 | ||||||
|
Non-cash royalty revenue related to sale of future royalties, net of withholding tax |
(2.7 |
) |
(2.3 |
) |
||||
|
Change in operating assets and liabilities: |
||||||||
|
Accounts receivables |
0.3 | (1.4 |
) |
|||||
|
Prepaid expenses and other current assets |
0.2 | (0.1 |
) |
|||||
|
Accounts payable and accrued expenses |
0.1 | 1.4 | ||||||
|
Net cash used in operating activities |
(9.2 |
) |
(19.7 |
) |
||||
|
Cash flows from investing activities: |
||||||||
|
Purchases of short and long-term investments |
(7.0 |
) |
(8.4 |
) |
||||
|
Maturities of short-term investments |
27.9 | 16.6 | ||||||
|
Net cash provided by investing activities |
20.9 |
8.2 | ||||||
|
Cash flows from financing activities: |
||||||||
|
Payment on note payable |
- | (0.1 |
) |
|||||
|
Net cash used in financing activities |
- | (0.1 |
) |
|||||
|
Increase (decrease) in cash and cash equivalents |
11.7 | (11.6 |
) |
|||||
|
Cash and cash equivalents at beginning of period |
17.7 | 49.7 | ||||||
|
Cash and cash equivalents at end of period |
$ | 29.4 | $ | 38.1 | ||||
The accompanying notes are an integral part of these condensed consolidated financial statements.
Aviragen Therapeutics, Inc.
Notes to the Condensed Consolidated Financial Statements (unaudited)
(for the quarterly period ended December 31, 2017)
|
1) |
Company Overview |
Aviragen Therapeutics, Inc., together with its wholly owned subsidiaries (“Aviragen”, or the “Company”) is a biopharmaceutical company focused on the discovery and development of direct-acting antivirals to treat infections that have limited therapeutic options and affect a significant number of patients globally. The Company has three Phase 2 clinical stage compounds: BTA074 (teslexivir), an antiviral treatment for condyloma caused by human papillomavirus types 6 & 11; vapendavir, a capsid inhibitor for the prevention or treatment of rhinovirus upper respiratory infections; and BTA585 (enzaplatovir), a fusion protein inhibitor in development for the treatment of respiratory syncytial virus (RSV) infections. The Company also has a preclinical RSV non-fusion inhibitor program. The Company is incorporated in the state of Delaware and its corporate headquarters are located in Alpharetta, Georgia.
Although several of the Company’s influenza product candidates have been successfully developed and commercialized to-date by other larger pharmaceutical companies under collaboration, license or commercialization agreements with the Company, it has not independently developed or received regulatory approval for any product candidate, and the Company does not currently have any sales, marketing or commercial capabilities. Therefore, it is possible that the Company may not successfully derive any significant product revenues from any product candidates that it is developing now, or may develop in the future. The Company expects to incur losses for the foreseeable future as it intends to support the clinical and preclinical development of its product candidates.
On October 30, 2017, the Company announced that it had entered into a definitive Agreement and Plan of Merger and Reorganization dated as of October 27, 2017, among the Company, Agora Merger Sub, Inc. and Vaxart, Inc. (the “Merger Agreement”) pursuant to which Vaxart, a privately-held clinical-stage company focused on developing oral recombinant vaccines from its proprietary delivery platform, would become a wholly-owned subsidiary of the Company (the “Merger”). This transaction marks the culmination of the Company’s Strategic Review process which was initiated in April. The Merger will result in a clinical-stage pharmaceutical company focused on developing Vaxart’s oral recombinant vaccines and Aviragen’s direct-acting antivirals to treat infections that have limited therapeutic options.
The exchange ratio in the merger agreement was determined by Vaxart assigning $60,000,000 in value to Aviragen for its financial and clinical assets, and $90,000,000 in value for its own assets. On a pro forma basis after giving effect to the number of shares of Aviragen common stock that will be issued to Vaxart security holders in the Merger and assuming no adjustments for cash balances as provided for in the Merger Agreement, current Vaxart security holders will own approximately 60% of the combined company and current Aviragen security holders will own approximately 40% of the combined company. The transaction has been approved by the boards of directors of both companies. The Merger is expected to close in February 2018, subject to the approval of the stockholders of each company as well as other customary conditions. Upon closing of the Merger, the name of the combined company will become Vaxart, Inc. and shares of the combined company are expected to continue trading on the NASDAQ Capital Market under the proposed ticker symbol VXRT. Wouter Latour, M.D., Chief Executive Officer of Vaxart, will serve as Chief Executive Officer of the combined company.
At the end of the quarter, a small group of dissident stockholders, who call themselves the Concerned Aviragen Shareholders (“CAS”) Group, launched a proxy contest against the proposed merger with Vaxart and are seeking an opportunity to nominate individuals for election to the Company’s Board at the upcoming Annual Meeting. The Company continues to believe the proposed merger with Vaxart is the best possible strategic alternative, and together, Aviragen and Vaxart will have the potential to create meaningful value for stockholders.
Prior to the completion of the proposed merger, the Company plans to continue to finance its operations with existing cash, cash equivalents and investments.
|
(2) |
Basis of Presentation |
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. All material adjustments considered necessary for a fair presentation have been included. Certain information and footnote disclosure normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to instructions, rules and regulations prescribed by the U.S. Securities and Exchange Commission (“SEC”). Except as disclosed herein, there has been no material change in the information disclosed in the notes to the condensed consolidated financial statements included in the Company’s Annual Report on Form 10-K that was filed with the SEC on September 1, 2017.
The unaudited interim condensed consolidated financial statements include the accounts of the Company and all of its wholly owned subsidiaries. All inter-company transactions and balances are eliminated in consolidation.
Operating results for the three and six months ended December 31, 2017 are not necessarily indicative of those in future quarters or the annual results that may be expected for the Company’s fiscal year ending June 30, 2018. For a more complete discussion of the Company’s significant accounting policies and other information, this report should be read in conjunction with the consolidated financial statements for the fiscal year ended June 30, 2017 included in the Company’s Annual Report on Form 10-K.
The Company’s significant accounting policies have not changed since June 30, 2017.
Recently Issued Accounting Standards
In May 2014, the FASB issued authoritative accounting guidance related to revenue from contracts with customers. This guidance is a comprehensive new revenue recognition model that requires a company to recognize revenue to depict the transfer of goods or services to a customer at an amount that reflects the consideration it expects to receive in exchange for those goods or services. This guidance is effective for annual reporting periods beginning after December 15, 2017. Accordingly, the Company will adopt this guidance on July 1, 2018. Companies may use either a full retrospective or a modified retrospective approach to adopt this guidance. The Company is evaluating which transition approach to use and its impact, if any, on its consolidated financial statements.
In January 2016, the FASB issued guidance related to financial instruments - overall recognition and measurement of financial assets and financial liabilities. The guidance enhances the reporting model for financial instruments, which includes amendments to address aspects of recognition, measurement, presentation and disclosure. The update to the standard is effective for public companies for interim and annual periods beginning after December 15, 2017. Accordingly, the standard is effective for the Company on July 1, 2018. The Company is currently evaluating the impact that the standard will have on the consolidated financial statements.
In February 2016, the FASB issued new guidance on leases. This guidance replaces the prior lease accounting guidance in its entirety. The underlying principle of the new standard is the recognition of lease assets and lease liabilities by lessees for substantially all leases, with an exception for leases with terms of less than twelve months. The standard also requires additional quantitative and qualitative disclosures. The guidance is effective for interim and annual reporting periods beginning after December 15, 2018, and early adoption is permitted. The standard requires a modified retrospective approach, which includes several optional practical expedients. Accordingly, the standard is effective for the Company on July 1, 2019. The Company is currently evaluating the impact that this guidance will have on the consolidated financial statements.
In August 2016, the FASB issued new guidance on how certain cash receipts and cash payments are presented and classified in the statement of cash flows. The standard is effective for the Company beginning July 1, 2018. Early adoption is permitted. We do not expect the adoption of this guidance to have a material impact on the consolidated financial statements.
|
(3) |
Fair Value Measurements |
A fair value hierarchy has been established that requires the Company to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value. The fair value hierarchy describes three levels of inputs that may be used to measure fair value:
|
Level 1 |
Quoted prices in active markets for identical assets or liabilities. |
|
Level 2 |
Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. |
|
|
Level 3 |
Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. |
The following table sets forth the financial assets and liabilities that were measured at fair value on a recurring basis at December 31, 2017 and June 30, 2017, by level within the fair value hierarchy. The assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.
The Company’s short-term investments as of June 30, 2017 have been classified as Level 2, which have been initially valued at the transaction price and subsequently revalued, at the end of each reporting period, utilizing a third party pricing service. The pricing service utilizes industry standard valuation models and observable market inputs to determine value that include surveying the bond dealer community, obtaining benchmark quotes, incorporating relevant trade data, and updating spreads daily. There have been no transfers of assets or liabilities between the fair value measurement classifications.
|
Quoted Prices in |
Significant |
|||||||||||||||
|
Active Markets |
Other |
Significant |
||||||||||||||
|
(in millions) |
for Identical Assets |
Observable Inputs |
Unobservable Inputs |
|||||||||||||
|
December 31, 2017 |
Total |
(Level 1) |
(Level 2) |
(Level 3) |
||||||||||||
|
Cash equivalents |
$ | 18.7 | $ | 7.0 | $ | 11.7 | $ | — | ||||||||
|
Short-term investments available-for-sale |
— | — | — | — | ||||||||||||
|
Total |
$ | 18.7 | $ | 7.0 | $ | 11.7 | $ | — | ||||||||
| (in millions) |
Quoted Prices in Active Markets for Identical Assets |
Significant Other Observable Inputs |
Significant Unobservable Inputs |
|||||||||||||
|
June 30, 2017 |
Total |
(Level 1) |
(Level 2) |
(Level 3) |
||||||||||||
|
Cash equivalents |
$ | 10.9 | $ | 5.9 | $ | 5.0 | $ | — | ||||||||
|
Short-term investments available-for-sale |
20.9 |
— | 20.9 | — | ||||||||||||
|
Total |
$ | 31.8 | $ | 5.9 | $ | 25.9 | $ | — | ||||||||
Cash equivalents consist primarily of money market funds, corporate notes and commercial paper with original maturities of 90 or fewer days when purchased. Short-term investments consist of certificates of deposit, corporate securities, U.S. Treasury securities and U.S. agency securities, classified as available-for-sale and have maturities less than 365 days from the date of acquisition.
The following table shows the unrealized gains and losses and fair values for those investments as of December 31, 2017 and June 30, 2017 aggregated by major security type:
|
(in millions) |
Unrealized |
Unrealized |
||||||||||||||
|
December 31, 2017 |
At Cost |
Gains |
(Losses) |
At Fair Value |
||||||||||||
|
Money market funds |
$ | 7.0 | $ | - | $ | - | $ | 7.0 | ||||||||
|
Corporate notes |
6.5 | - | - | 6.5 | ||||||||||||
|
Commercial paper |
5.2 | - | - | 5.2 | ||||||||||||
|
Total |
$ | 18.7 | $ | - | $ | - | $ | 18.7 | ||||||||
|
(in millions) |
Unrealized |
Unrealized |
||||||||||||||
|
June 30, 2017 |
At Cost |
Gains |
(Losses) |
At Fair Value |
||||||||||||
|
Money market funds |
$ | 5.9 | $ | — | $ | — | $ | 5.9 | ||||||||
|
Commercial paper |
8.5 | — | — | 8.5 | ||||||||||||
|
Corporate notes |
17.4 | — | — | 17.4 | ||||||||||||
|
Total |
$ | 31.8 | $ | — | $ | — | $ | 31.8 | ||||||||
As of December 31, 2017 and June 30, 2017, the Company had investments in an unrealized gain (loss) position below material disclosure thresholds in the table above. The Company determined that the unrealized gains and losses on these investments were temporary in nature and expected the security to mature at its stated maturity principal. All available-for-sale securities held at December 31, 2017, will mature in less than one year. The fair value of cash, accounts receivable, accounts payable and accrued liabilities approximate their carrying value because of the short-term nature of these financial instruments at December 31, 2017 and June 30, 2017, respectively. The fair value of the Company’s short-term note payable, which is measured using Level 2 inputs, approximates book value, at December 31, 2017 and June 30, 2017.
(4) Accrued and Other Current Liabilities
Accrued expenses consist of the following (in millions):
|
December 31, 2017 |
June 30, 2017 |
|||||||
|
Professional fees |
$ | 0.7 | $ | 0.4 | ||||
|
Salary and benefits |
1.3 | 0.4 | ||||||
|
Research and development expenses |
0.5 | 1.8 | ||||||
|
Other accrued expenses |
- | 0.3 | ||||||
|
Total accrued expenses and other liabilities |
$ | 2.5 | $ | 2.9 | ||||
(5) Liabilities Related to Sale of Future Royalties
In April 2016, the Company sold certain royalty rights related to the approved product Inavir®, sold by Daiichi Sankyo Company, Limited (“Daiichi Sankyo”) in the Japanese market, for $20 million to HealthCare Royalty Partners III, L.P. (“HCRP”). Under the relevant accounting guidance, due to a limit on the amount of royalties that HCRP can earn under the arrangement, this transaction was accounted for as a liability that will be amortized using the interest method over the life of the arrangement. The Company has no obligation to pay any amounts to HCRP other than to pass through to HCRP its share of royalties as they are received from Daiichi Sankyo. In order to record the amortization of the liability, the Company is required to estimate the total amount of future royalty payments to be received under the License Agreement with Daiichi Sankyo and the payments that will be passed through to HCRP over the life of the agreement. The sum of the pass through amounts less the net proceeds received will be recorded as non-cash interest expense over the life of the liability. Consequently, the Company imputes interest on the unamortized portion of the liability and records non-cash interest expense using an estimated effective interest rate. The Company will periodically assess the expected royalty payments, and to the extent such payments are greater or less than the initial estimate, the Company will adjust the amortization of the liability and interest rate. As a result of this accounting, even though the Company does not retain HCRP’s share of the royalties, it will continue to record non-cash revenue related to those royalties until the amount of the associated liability and related interest is fully amortized.
The following table shows the activity within the liability account during the six months ended December 31, 2017:
|
in millions |
||||
|
Total Liability related to sale of future royalties, June 30, 2017 |
$ | 16.7 | ||
|
Non-cash royalty revenue paid to HCRP |
(0.3 | ) | ||
|
Non-cash interest expense recognized |
0.8 | |||
|
Total Liability related to sale of future royalties, December 31, 2017 |
$ | 17.2 | ||
(6) Net Loss per share
Basic and diluted net loss per share has been computed based on net loss and the weighted-average number of common shares outstanding during the applicable period. For diluted net loss per share, common stock equivalents (shares of common stock issuable upon the exercise of stock options and unvested restricted stock units) are excluded from the calculation as their inclusion would be anti-dilutive. The Company has excluded all anti-dilutive share-based awards to purchase common stock in periods indicating a loss, as their effect is anti-dilutive.
The following tables set forth the computation of historical basic and diluted net loss per share.
|
Three Months Ended |
||||||||
|
2017 |
2016 |
|||||||
|
Net loss (in millions) |
$ | (3.4 |
) |
$ | (9.1 |
) |
||
|
Weighted-average shares outstanding |
38,649,237 | 38,640,487 | ||||||
|
Dilutive effect of restricted stock and stock options |
- | - | ||||||
|
Shares used to compute diluted earnings per share |
38,649,237 | 38,640,487 | ||||||
|
Basic net loss per share |
$ | (0.09 |
) |
$ | (0.24 |
) |
||
|
Diluted net loss per share |
$ | (0.09 |
) |
$ | (0.24 |
) |
||
|
Number of anti-dilutive share-based awards excluded from computation |
6,898,629 | 5,645,543 | ||||||
|
Six Months Ended |
||||||||
|
2017 |
2016 |
|||||||
|
Net loss (in millions) |
$ | (8.7 |
) |
$ | (19.1 |
) |
||
|
Weighted-average shares outstanding |
38,649,237 | 38,640,487 | ||||||
|
Dilutive effect of restricted stock and stock options |
- | - | ||||||
|
Shares used to compute diluted earnings per share |
38,649,237 | 38,640,487 | ||||||
|
Basic net loss per share |
$ | (0.23 |
) |
$ | (0.49 |
) |
||
|
Diluted net loss per share |
$ | (0.23 |
) |
$ | (0.49 |
) |
||
|
Number of anti-dilutive share-based awards excluded from computation |
6,898,629 | 5,645,543 | ||||||
|
(7) |
Licenses, Royalty Collaborative and Contractual Arrangements |
Royalty agreements
The Company entered into a royalty-bearing research and license agreement with GlaxoSmithKline (“GSK”) in 1990 for the development and commercialization of zanamivir, a neuraminidase inhibitor marketed by GSK as Relenza® to treat influenza. Under the terms of the agreement, the Company licensed zanamivir to GSK on an exclusive, worldwide basis. Most of the Company’s Relenza® patents have expired and the only substantial remaining intellectual property related to the Relenza® patent portfolio is scheduled to expire in July 2019 in Japan. Until that patent expires, the Company will receive a 7% royalty on GSK’s annual net sales of Relenza® in Japan.
The Company also generates royalty revenue from the sale of Inavir® (laninamivir octanoate or LANI) in Japan, pursuant to a collaboration and license agreement and a related commercialization agreement (collectively, the “Inavir® License Agreement”) with Daiichi Sankyo. Under the Inavir® License Agreement, the Company currently receives a 4% royalty on net sales of Inavir® in Japan and is eligible to earn sales milestone payments. Under the Inavir® License Agreement, the Company and Daiichi Sankyo have cross-licensed the world-wide rights to develop and commercialize the related intellectual property, and have agreed to share equally in any royalties, license fees, or milestone or other payments received from any third party licenses outside of Japan. The patent relating to hydrates and the crystalline form of LANI used in Inavir® expires in 2021 (not including extensions) in the U.S. and EU and in 2024 in Japan. In February 2015, a patent containing claims relevant to the manufacture of Inavir® was issued in Japan and expires in December 2029.
In April 2016, the Company entered into a Royalty Interest Acquisition Agreement (“Agreement”) with HCRP. Under the Agreement, HCRP made a $20 million cash payment to the Company in consideration for acquiring from the Company certain royalty rights (“Royalty Rights”) related to Inavir® in the Japanese market.
The following tables summarize the key components of the Company’s revenues (in millions):
|
Three Months Ended December 31, |
||||||||
|
2017 |
2016 |
|||||||
|
(in millions) |
||||||||
|
Royalty revenue - Relenza® |
$ | - | $ | 1.5 | ||||
|
Non-cash royalty revenue related to the sale of future royalties |
2.7 | 2.3 | ||||||
|
Total revenue |
$ | 2.7 | $ | 3.8 | ||||
|
Six Months Ended December 31, |
||||||||
|
2017 |
2016 |
|||||||
|
(in millions) |
||||||||
|
Royalty revenue - Relenza® |
$ | - | $ | 1.6 | ||||
|
Non-cash royalty revenue related to the sale of future royalties |
2.8 | 2.3 | ||||||
|
Total revenue |
$ | 2.8 | $ | 3.9 | ||||
Relenza revenue declined to zero in the three and six months ended December 31, 2017 from $1.5 million in the same periods of the prior fiscal year due to the cessation of royalties on U.S. sales at the end of 2016 and the unfavorable impact of a returns adjustment in the current quarter.
Collaborative and contract arrangements
In July 2016, the Company entered into an exclusive, worldwide license for RSV replication inhibitors intellectual property with Georgia State University Research Foundation (“GSURF”) in exchange for an upfront fee, future milestone payments and royalties on future net sales of any products that utilize the underlying RSV intellectual property. The Company has an obligation to make a minimum payment of $10,000 to GSURF annually until the license agreement expires or is terminated. The Company also entered into a two year sponsored research agreement with GSURF for annual sponsored research payments.
|
(8) |
Income Taxes |
On December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (the “Tax Act”). The Tax Act significantly revises the future ongoing U.S. corporate income tax by, among other things, lowering U. S. corporate income tax rates and implementing a territorial tax system. Since the Company is a calendar year tax filer, the lower corporate income tax rate will be effective beginning January 1, 2018.
Based upon the provisions of the Tax Act, the Company’s deferred tax assets and liabilities will be remeasured to incorporate the lower corporate tax rate of 21% into its tax provision; however, since the Company maintains a full valuation allowance, there is no net impact to income tax expense reported in the Company’s financial statements for the periods presented as the provisional valuation allowance will be adjusted accordingly. At this time, the Company is still evaluating the impact of this remeasurement.
There are also certain transitional impacts of the Tax Act. As part of the transition to the new territorial tax system, the Tax Act imposes a one-time repatriation tax on deemed repatriation of historical earnings and profits (“E&P”) of foreign subsidiaries. Due to the complexity of this calculation and the information required to complete such a calculation, the Company is still reviewing its E&P from our foreign subsidiaries in connection with the one-time transition tax.
The Company is also currently analyzing its global working capital and cash requirements and the potential tax liabilities attributable to a repatriation, including calculating any excess of the amount for financial reporting over the tax basis in its foreign subsidiaries, but has yet to determine whether it plans to change its prior assertion and repatriate earnings. Accordingly, the Company has not recorded any deferred taxes attributable to its investments in its foreign subsidiaries. The Company will record the tax effects of any change in its prior assertion in the period that it completes its analysis and are able to make a reasonable estimate, and disclose any unrecognized deferred tax liability for temporary differences related to its foreign investments, if practicable.
The changes included in the Tax Act are broad and complex. The final transition impacts of the Tax Act may affect our financial statements and/or disclosures, possibly materially, due to, among other things, changes in interpretations of the Tax Act, any legislative action to address questions that arise because of the Tax Act, any changes in accounting standards for income taxes or related interpretations in response to the Tax Act. The Securities Exchange Commission has issued rules that would allow for a measurement period of up to one year after the enactment date of the Tax Act to finalize the recording of the related tax impacts.
ITEM 2: Management’s Discussion and Analysis of Financial Condition and Results of Operations
FORWARD LOOKING STATEMENTS
This Quarterly Report on Form 10-Q contains forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In most cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “could,” “would,” “expect,” “plan,” “intend,” “anticipate,” “believe,” “estimate,” “project,” “predict,” “forecast,” “potential,” “likely” or “possible”, as well as the negative of such expressions, and similar expressions intended to identify forward-looking statements. These forward-looking statements include, without limitation, statements relating to:
|
● |
our expectations as to when top-line safety and efficacy data for BTA074 (teslexivir) are expected; |
|
● |
our anticipation that we will generally incur net losses from operations in the future due to our intention to continue to support the preclinical and clinical development of our product candidates; |
|
● |
our future financing requirements, the factors that may influence the timing and amount of those requirements and our ability to fund them; |
|
● |
the number of months that our current cash, cash equivalents, investments and anticipated future proceeds from existing royalty-bearing licenses will allow us to operate; and |
|
● |
the expected post-Merger share ownership split between Vaxart and Aviragen stockholders and anticipated timing of the closing of the Merger. |
Various important factors could cause actual results, performance, events or achievements to materially differ from those expressed or implied by forward-looking statements, including the U.S. Food and Drug Administration (“FDA”) or a similar regulatory body in another country, a data safety monitoring board, or an institutional review board delaying, limiting, suspending or terminating any of the Company’s clinical development programs at any time for a lack of safety, efficacy, tolerability, anti-viral activity, commercial viability, regulatory or manufacturing issues, or any other reason whatsoever; the Company's ability to secure, manage and retain qualified third-party clinical research, preclinical research, data management and contract manufacturing organizations upon which it relies to assist in the design, development, implementation and execution of the clinical and preclinical development of all its product candidates; and these third-party organizations fulfilling their contractual obligations on a timely and satisfactory basis; the safety or efficacy data from planned or ongoing future preclinical and clinical studies of any of its product candidates not supporting the clinical development of that product candidate; the successful enrollment of the requisite number of study participants on a timely basis; the Company’s ability to comply with applicable government regulations in various countries and regions in which we are conducting, or expect to conduct, clinical trials; the Company’s ability to retain and recruit sufficient staff, including key executive management and employees, to manage our business; the Company’s ability to maintain, protect or defend its proprietary rights from unauthorized use by others, or not infringe on the intellectual property rights of others; our ability to successfully manage our expenses, operating results and financial position in line with our plans and expectations; the condition of the financial equity and debt markets and our ability to raise sufficient funding in such markets; changes in the general economic business or competitive conditions in the industry or with respect to our product candidates; potential employee resignations on short notice; provisions in certificate of incorporation, bylaws and laws of Delaware containing provisions that could delay or discourage a change in control of the Company; the Company’s obtaining the requisite stockholder approval and other conditions to the Merger being satisfied; and other cautionary statements contained elsewhere in this Quarterly Report on Form 10-Q and in the Company’s Annual Report on Form 10-K for the year ended June 30, 2017, as filed with the U.S. Securities and Exchange Commission on September 1, 2017.
There may be events in the future that we are unable to predict accurately, or over which we have no control. You should completely read this Form 10-Q and the documents that we reference herein that have been filed or incorporated by reference as exhibits and with the understanding that our actual future results may be materially different from what we expect. Our business, financial condition, results of operations, and prospects may change. We may not update these forward-looking statements, even though our situation may change in the future, unless we have an obligation under the federal securities laws to update and disclose material developments related to previously disclosed information. We qualify all of the information presented in this Form 10-Q, and particularly our forward-looking statements, by these cautionary statements.
Aviragen is a registered trademark of Aviragen Therapeutics Inc., Relenza® is a registered trademark of GlaxoSmithKline plc, and Inavir® is a registered trademark of Daiichi Sankyo Company, Ltd.
References to “we,” “us,” and “our” refer to Aviragen Therapeutics, Inc. and its subsidiaries.
The following is a discussion and analysis of the major factors contributing to our results of operations for the three and six months ended December 31, 2017, and our financial condition at that date, and should be read in conjunction with the financial statements and the notes thereto included in Part I, Item 1 of this Quarterly Report on Form 10-Q.
Company Overview
We are focused on the discovery and development of direct-acting antivirals to treat infections that have limited therapeutic options and affect a significant number of patients globally. The Company has three Phase 2 clinical stage compounds: BTA074 (teslexivir), an antiviral treatment for condyloma caused by human papillomavirus types 6 & 11; vapendavir, a capsid inhibitor for the prevention or treatment of rhinovirus (“RV”) upper respiratory infections; and BTA585 (enzaplatovir), a fusion protein inhibitor in development for the treatment of respiratory syncytial virus infections.
Although several of our influenza product candidates have been successfully developed and commercialized to date by other larger pharmaceutical companies under license, collaboration or commercialization agreements with us, we have not independently developed or received regulatory approval for any product candidate, and we do not currently have any sales, marketing or commercial capabilities. Therefore, it is possible that we may not derive any significant product revenues from any product candidates that we are developing now, or may develop in the future. We expect to incur losses for the foreseeable future as we intend to support the clinical and preclinical development of our product candidates.
On October 30, 2017, the Company announced that it had entered into the Merger Agreement pursuant to which Vaxart, a privately-held clinical-stage company focused on developing oral recombinant vaccines from its proprietary delivery platform, would become a wholly-owned subsidiary of the Company. This transaction marks the culmination of the Company’s Strategic Review process which was initiated in April. The Merger will result in a clinical-stage pharmaceutical company focused on developing Vaxart’s oral recombinant vaccines and our direct-acting antivirals to treat infections that have limited therapeutic options. We believe Vaxart’s oral tablet vaccines have the potential to be major products in the worldwide vaccine market.
The exchange ratio in the merger agreement was determined by Vaxart assigning $60,000,000 in value to Aviragen for its financial and clinical assets, and $90,000,000 in value for its own assets. On a pro forma basis after giving effect to the number of shares of Aviragen common stock that will be issued to Vaxart security holders in the Merger and assuming no adjustments for cash balances as provided for in the Merger Agreement, current Vaxart security holders will own approximately 60% of the combined company and current Aviragen security holders will own approximately 40% of the combined company. The transaction has been approved by the boards of directors of both companies. The Merger is expected to close in February 2018, subject to the approval of the stockholders of each company as well as other customary conditions.
At the end of the quarter, a small group of dissident stockholders, who call themselves the Concerned Aviragen Shareholders (“CAS”) Group, launched a proxy contest against the proposed merger with Vaxart and are seeking an opportunity to nominate individuals for election to the Company’s Board at our upcoming Annual Meeting. We continue to believe the proposed merger with Vaxart is the best possible strategic alternative, and together, Aviragen and Vaxart will have the potential to create meaningful value for stockholders.
CRITICAL ACCOUNTING POLICIES AND ESTIMATES
Management’s Discussion and Analysis of Results of Operations discusses our financial results, which (except to the extent described in the Notes thereto) have been presented in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). The preparation of financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.
We base our estimates and judgments on historical experience, current economic and industry conditions, and various other factors that we believe to be reasonable under the circumstances. This forms the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. We believe there have been no changes to our critical accounting policies that require significant judgment and estimates as discussed in detail in our 2017 annual 10-K filing:
|
• |
Use of estimates |
|
|
• |
Revenue recognition |
|
|
• |
Accrued expenses |
|
|
• |
Share-based compensation |
For a description of recent accounting policies and the impact on our financial statements, refer to Note 2 in the condensed consolidated financial statements.
Results of Operations for the Three months ended December 31, 2017 and December 31, 2016
Summary. For the three months ended December 31, 2017, we reported a net loss of $3.4 million, as compared to a net loss of $9.1 million in the same period of the prior fiscal year. Basic and diluted net loss per share was $0.09 for the three month period ended December 31, 2017, as compared to a basic and diluted net loss per share of $0.24 in the same period of 2016. The following commentary provides details underlying changes from last year in the major line items of our statement of operations:
Revenue. Revenue decreased to $2.7 million for the three month periods ended December 31, 2017, as compared to $3.8 million in the same period in 2016, mostly due to a decrease in our Relenza royalties. Relenza revenue declined to zero in the three months ended December 31, 2017 from $1.5 million in the same period of the prior fiscal year due to the cessation of royalties on U.S. sales at the end of 2016 and the unfavorable impact of a returns adjustment in the current quarter. The following table summarizes the key components of our revenue for the three months ended December 31, 2017 and 2016:
|
Three Months Ended December 31, |
||||||||
|
2017 |
2016 |
|||||||
|
(in millions) |
||||||||
|
Royalty revenue - Relenza® |
$ | - | $ | 1.5 | ||||
|
Non-cash royalty revenue related to the sale of future royalties |
2.7 | 2.3 | ||||||
|
Total revenue |
$ | 2.7 | $ | 3.8 | ||||
Research and Development Expense. Research and development expense decreased to $2.5 million for the three months ended December 31, 2017 from $10.2 million for the same period in 2016. The following table summarizes the components of our research and development expense for the three months ended December 31, 2017 and 2016.
|
Three Months Ended December 31, |
||||||||
|
(in millions) |
||||||||
|
2017 |
2016 |
|||||||
|
Direct preclinical, clinical and product development expenses |
$ | 1.4 | $ | 9.0 | ||||
|
Salaries, severance and share-based compensation expenses |
1.1 | 1.1 | ||||||
|
Depreciation and facility related expenses |
- | 0.1 | ||||||
|
Total research and development expense |
$ | 2.5 | $ | 10.2 | ||||
Direct preclinical, clinical and product development expense decreased largely due to reduced clinical trial activity and manufacturing costs, as two of our three Phase 2 clinical trials came to a close at the end of the prior fiscal year. Salaries, severance and share-based compensation expenses did not change as compared to the same period in 2016, as decreases due to reductions in personnel in the last quarter of the prior fiscal year were offset by severance expense for employees terminated in the current quarter.
General and Administrative Expense. General and administrative expense increased to $3.1 million for the three months ended December 31, 2017 from $2.1 million for the same period in 2016, largely due to legal and professional fees related to the proposed merger with Vaxart announced in October 2017 and severance due to a reduction in personnel. The following table summarizes the components of our general and administrative expense for the three months ended December 31, 2017 and 2016.
|
Three Months Ended December 31, |
||||||||
|
(in millions) |
||||||||
|
2017 |
2016 |
|||||||
|
Salaries, benefits and share-based compensation expenses |
$ | 1.2 | $ | 1.1 | ||||
|
Professional and legal fees expenses |
1.4 | 0.4 | ||||||
|
Other expenses |
0.5 | 0.6 | ||||||
|
Total general and administrative expense |
$ | 3.1 | $ | 2.1 | ||||
Foreign Exchange Loss (Gain), net. The impact of foreign exchange changed from a loss of $0.1 million in December 31, 2016 to no gain or loss for three months ended December 31, 2017. The positive impact on foreign exchange on our statement of operations was due to fluctuations in foreign currency exchange rates versus the U.S. dollar, largely related to the British Pound and Australian dollar. The vast majority of our cash holdings are held in the U.S. dollar. We re-measure all of our foreign assets and liabilities at the period-end exchange rate and the net effect of these translation adjustments is shown as a foreign currency loss or gain.
Results of Operations for the Six months ended December 31, 2017 and December 31, 2016
Summary. For the six months ended December 31, 2017, we reported a net loss of $8.7 million, as compared to a net loss of $19.1 million in the same period of the prior fiscal year. Basic and diluted net loss per share was $0.23 for the six month period ended December 31, 2017, as compared to a basic and diluted net loss per share of $0.49 in the same period of 2016. The following commentary provides details underlying changes from last year in the major line items of our statement of operations:
Revenue. Revenue decreased to $2.8 million for the six month periods ended December 31, 2017, as compared to $3.9 million in the same period in 2016, mostly due to a decrease in our Relenza royalties. Relenza revenue declined to zero in the six months ended December 31, 2017 from $1.6 million in the same period of the prior fiscal year due to the cessation of royalties on U.S. sales at the end of 2016 and the unfavorable impact of a returns adjustment in the current year. The following table summarizes the key components of our revenue for the six months ended December 31, 2017 and 2016:
|
Six Months Ended December 31, |
||||||||
|
2017 |
2016 |
|||||||
|
(in millions) |
||||||||
|
Royalty revenue - Relenza® |
$ | - | $ | 1.6 | ||||
|
Non-cash royalty revenue related to the sale of future royalties |
2.8 | 2.3 | ||||||
|
Total revenue |
$ | 2.8 | $ | 3.9 | ||||
Research and Development Expense. Research and development expense decreased to $5.3 million for the six months ended December 31, 2017 from $17.8 million for the same period in 2016. The following table summarizes the components of our research and development expense for the six months ended December 31, 2017 and 2016.
|
Six Months Ended December 31, |
||||||||
|
(in millions) |
||||||||
|
2017 |
2016 |
|||||||
|
Direct preclinical, clinical and product development expenses |
$ | 3.3 | $ | 15.4 | ||||
|
Salaries, severance and share-based compensation expenses |
1.9 | 2.2 | ||||||
|
Depreciation and facility related expenses |
0.1 | 0.2 | ||||||
|
Total research and development expense |
$ | 5.3 | $ | 17.8 | ||||
Direct preclinical, clinical and product development expense decreased largely due to reduced clinical trial activity and manufacturing costs, as two of our three Phase 2 clinical trials came to a close at the end of the prior fiscal year. Salaries, severance and share-based compensation expenses decreased compared to the same period in 2016 due to a reduction in personnel in the last quarter of the prior fiscal year, partially offset by severance expense for employees terminated in the current year.
General and Administrative Expense. General and administrative expense increased to $5.4 million for the six months ended December 31, 2017 from $4.3 million for the same period in 2016, largely due to legal and professional fees related to the proposed merger with Vaxart announced in October 2017 and severance due to a reduction in personnel. The following table summarizes the components of our general and administrative expense for the six months ended December 31, 2017 and 2016.
|
Six Months Ended December 31, |
||||||||
|
(in millions) |
||||||||
|
2017 |
2016 |
|||||||
|
Salaries, benefits and share-based compensation expenses |
$ | 2.3 | $ | 2.0 | ||||
|
Professional and legal fees expenses |
2.0 | 1.1 | ||||||
|
Other expenses |
1.1 | 1.2 | ||||||
|
Total general and administrative expense |
$ | 5.4 | $ | 4.3 | ||||
LIQUIDITY AND CAPITAL RESOURCES
For the six months ended December 31, 2017, cash and cash equivalents increased by $11.7 million. This increase was primarily the result of the maturities of our short-term investments.
Net cash used by operating activities was $9.2 million for the six months ended December 31, 2017, which reflected our net loss during the period of $8.7 million, a net decrease in a net operating assets of $0.5 million and a decrease in operating liabilities of $0.1 million, partially offset by net non-cash adjustments of $1.1 million. Non-cash adjustments consist of $2.7 million in non-cash royalty income, net of withholding taxes, partially offset by $0.8 million in non-cash interest expense and $0.8 million in share-based compensation expense.
Our net loss resulted largely from our funding of research and development activities including conducting the CT4 clinical trial for BTA074 (teslexivir), as well as ongoing general and administrative expenses including legal and professional fees related to the proposed merger with Vaxart. The net changes in operating assets and liabilities primarily reflects a $0.1 million decrease in accounts payable and accrued expense due to reduced clinical trial activity, offset by a $0.2 million decrease in prepaid expenses, also due to reduced clinical trial activity and a $0.3 million decrease in cash receivables primarily related to receipt of a research and development tax credit.
Net cash provided by investing activities during the six months ended December 31, 2017 consisted of the maturity of $27.9 million of investments, partially offset by the purchase of $7.0 million of investments.
At December 31, 2017, our cash and cash equivalents totaled $29.4 million. Our cash and cash equivalents are currently held in the form of short-term deposits with large U.S. banks, commercial paper and highly-rated corporate securities.
Based on our current strategy and operating plan, and considering the potential costs associated with advancing the preclinical and clinical development of our product candidates, we believe that our existing cash and cash equivalents of approximately $29.4 million as of December 31, 2017, along with the anticipated proceeds from existing royalty-bearing licenses will enable us to operate for a period of at least 12 months from the date of this report.
We have an ATM facility in place, which may allow us to quickly access the equity capital markets if we think it is prudent to do so and if market conditions allow. However, we currently do not have any commitments for future funding, nor do we anticipate that we will generate significant revenue, aside from revenue from existing royalty-bearing arrangements.
Contractual and Commercial Commitments
There have been no material changes from the information included in our Annual Report on Form 10-K for the fiscal year ended June 30, 2017.
Off-Balance Sheet Arrangements
We do not have any off-balance sheet arrangements, as defined in Item 303(a)(4) (ii) of Regulation S-K under the Securities Exchange Act of 1934, as amended.
ITEM 3: Quantitative and Qualitative Disclosures about Market Risk
There has been no material change in our assessment of sensitivity to market risk since our presentation set forth in Item 7A “Quantitative and Qualitative Disclosures about Market Risk” in the our Annual Report on Form 10-K for the fiscal year ended June 30, 2017.
ITEM 4: Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Our management, including our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this report. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this report.
Changes in Internal Controls over Financial Reporting
There has been no change in our internal control over financial reporting during the quarter ended December 31, 2017 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
The Company is involved in various legal proceedings that are incidental to the conduct of its business. The Company is not involved in any pending or threatened legal proceedings that it believes could reasonably be expected to have a material adverse effect on its financial condition or results of operations.
Any investment in our business involves a high degree of risk. Before making an investment decision, you should carefully consider the information we include in this Quarterly Report on Form 10-Q, including our condensed consolidated financial statements and accompanying notes, and the additional information in the other reports we file with the Securities and Exchange Commission along with the risks described in our Annual Report on Form 10-K for the fiscal year ended June 30, 2017. The Company is also subject to the risk factors set forth under the captions “Risks Related to the Merger,” “Risks Related to Aviragen” and “Risks Related to the Combined Company” in the Prospectus that is part of the Registration Statement on Form S-4 (File No. 333-222009), as amended, filed with the Securities and Exchange Commission by the Company and declared effective on December 29, 2017. We have also described below those risks that reflect substantive changes from, or additions to, the risks described in our Annual Report on Form 10-K and Form S-4, as amended, referred to above. These risks may result in material harm to our business and our financial condition and results of operations. In this event, the market price of our common stock may decline and you could lose part or all of your investment.
We may be subject to the actions of activist shareholders.
We have been the subject of increased activity by activist shareholders, including Digirad Corporation, East Hill Management Company, LLC, Thomas M. Clay, and certain other investors (collectively, the “Activist Group”). Responding to shareholder activism can be costly and time-consuming, disrupt our operations and divert the attention of management and our employees. Activist campaigns, including the Activist Group’s ongoing campaign against our proposed transaction with Vaxart and the Activist Group’s notice of its intention to nominate a competing director slate for election at our annual stockholder meeting scheduled for April 11, 2018, can create uncertainties as to our future direction, strategy and leadership and may result in the loss of potential business opportunities and cause our stock price to experience periods of volatility. Moreover, if individuals are elected to our board of directors with a specific agenda, our ability to effectively and timely implement our current initiatives, retain and attract experienced executives and employees and execute on our current business strategy may be adversely affected.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
None.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
Not applicable.
ITEM 4. MINE SAFETY DISCLOSURE
Not applicable.
None.
The exhibits to this report are listed in the Exhibit Index, which is incorporated into this Item 6 by reference.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
Aviragen Therapeutics, Inc. |
|
|
|
|
|
|
|
Date: February 6, 2018 |
By: |
/s/ Joseph M. Patti |
|
|
|
|
Joseph M. Patti Chief Executive Officer (Principal Executive Officer) |
|
|
|
|
|
|
|
|
By: |
/s/ Mark P. Colonnese |
|
|
|
|
Mark P. Colonnese Executive Vice President and Chief Financial Officer (Principal Financial Officer) |
|
|
|
|
|
|
Filed |
|
Incorporation by Reference |
||||
|
Exhibit Number |
|
Exhibit Title |
|
with this Form 10-Q |
|
Form |
|
File No. |
|
Date Filed |
|
2.1 |
8-K |
001-35285 171160761 |
10-30-2017 |
|||||||
|
2.2 |
8-K |
001-35285 171160761 |
10-30-2017 |
|||||||
|
2.3 |
8-K |
001-35285 171160761 |
10-30-2017 |
|||||||
|
31.1* |
|
|
X |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
31.2* |
|
|
X |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
32.1* |
|
|
X |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
101 |
|
The following financial information from the Aviragen Therapeutics, Inc. Quarterly Report on Form 10-Q for the period ended December 31, 2017 formatted in Extensible Business Reporting Language (XBRL): (i) the Condensed Consolidated Balance Sheets, (ii) the Condensed Consolidated Statements of Operations for the Three months, (iii) the Condensed Statements of Stockholders’ Equity, (iv) Condensed Consolidated Statements of Cash Flows, and (v) Notes to Condensed Consolidated Financial Statements |
|
X |
|
|
|
|
|
|
* This certification is being furnished solely to accompany this quarterly report pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934 and is not to be incorporated by reference into any filing of Aviragen Therapeutics, Inc., whether made before or after the date hereof, regardless of any general incorporation language in such filing.
23